LeMaitre Vascular Files 8-K on Financial Results
Ticker: LMAT · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1158895
| Field | Detail |
|---|---|
| Company | Lemaitre Vascular Inc (LMAT) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-K, corporate-filing
TL;DR
**LeMaitre Vascular just filed an 8-K reporting financial results, but the actual numbers aren't in this snippet.**
AI Summary
LeMaitre Vascular, Inc. (CIK: 0001158895) filed an 8-K on February 27, 2024, reporting on its "Results of Operations and Financial Condition" and "Financial Statements and Exhibits." The filing, under SEC File Number 001-33092, indicates the company is providing an update on its financial performance, though specific figures are not included in this excerpt.
Why It Matters
This 8-K signals that LeMaitre Vascular, Inc. is disclosing its latest financial performance, which is crucial for investors to assess the company's health and make informed decisions.
Risk Assessment
Risk Level: low — This 8-K merely announces the reporting of financial results and exhibits, without disclosing any specific positive or negative financial outcomes in the provided text.
Key Players & Entities
- LeMaitre Vascular, Inc. (company) — registrant
- United States Securities and Exchange Commission (company) — regulatory body
- Burlington, MA (location) — business address
- Delaware (location) — state of incorporation
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is LeMaitre Vascular, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 27, 2024.
What is the Commission File Number for LeMaitre Vascular, Inc.?
The Commission File Number is 001-33092.
What specific items are reported in this 8-K filing?
The 8-K reports on "Results of Operations and Financial Condition" and "Financial Statements and Exhibits."
Where is LeMaitre Vascular, Inc.'s principal executive office located?
Its principal executive office is located at 63 Second Avenue, Burlington, MA 01803.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-02-27 17:01:09
Key Financial Figures
- $0.01 — nge on which registered Common stock , $0.01 par value per share LMAT The Nasdaq
Filing Documents
- lmat20240227_8k.htm (8-K) — 30KB
- ex_631464.htm (EX-99.1) — 422KB
- 0001437749-24-005732.txt ( ) — 602KB
- lmat-20240227.xsd (EX-101.SCH) — 3KB
- lmat-20240227_def.xml (EX-101.DEF) — 11KB
- lmat-20240227_lab.xml (EX-101.LAB) — 15KB
- lmat-20240227_pre.xml (EX-101.PRE) — 11KB
- lmat20240227_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 27, 2024, LeMaitre Vascular, Inc. (the "Company") issued a press release regarding its preliminary financial and operational results for the quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Report. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Disclaimer on Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. The following exhibits are furnished or filed as part of this Report, as applicable: (d) Exhibits. Exhibit No. Description 99.1 Press release issued by LeMaitre Vascular, Inc. on February 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature(s) Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LeMaitre Vascular, Inc. Date: February 27, 2024 By: Joseph P. Pellegrino, Jr. /s/ JOSEPH P. PELLEGRINO, JR. Joseph P. Pellegrino, Jr. Chief Financial Officer Exhibit Index Exhibit No. Description 99.1 Press release issued by LeMaitre Vascular, Inc. on February 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)